4.6 Article

Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors

Journal

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biocel.2016.01.003

Keywords

FOXL2; Ovary; Ovarian cancer; Granulosa cell tumor

Funding

  1. Cancer Council Victoria
  2. Ovarian Cancer Research Foundation
  3. Granulosa Cell Tumor of the Ovary Foundation
  4. National Health & Medical Research Council of Australia [1058334, 1002559]
  5. Victorian Government's Operational Infrastructure Scheme
  6. National Health and Medical Research Council of Australia [1058334] Funding Source: NHMRC

Ask authors/readers for more resources

Granulosa cell tumors (GCT) are unique sex-cord stromal tumors which account for similar to 8% of all ovarian malignancies. They exhibit morphological, biochemical and hormonal features similar to proliferating granulosa cells of the preovulatory follicle, including estrogen and inhibin synthesis. A somatic missense mutation in the forkhead box L2 (FOXL2) gene (C134W) is unique to adult GCT, and absent in other ovarian cancers. FOXL2 is a transcription factor that plays a critical role in ovarian function, in particular, proliferation and differentiation of granulosa cells. The molecular mechanisms underlying the pathogenicity of the mutant FOXL2 remain unresolved. Here we review the molecular alterations known to be associated with mutant FOXL2 and the potential signaling implications. Several studies suggest that dysregulated FOXL2 function may alter cell cycle progression and apoptosis. Further insights into the molecular mechanism of GCT pathophysiology may identify therapeutic targets for the treatment of these tumors. (C) 2016 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available